Kiniksa Pharmaceuticals Ltd (NASDAQ:KNSA), a biopharmaceutical company focused on the discovery, acquisition, development, and commercialization of therapeutics for patients suffering from debilitating diseases with significant unmet medical need, has reported an insider sale according to a recent SEC filing.
Michael Megna, the Chief Accounting Officer of Kiniksa Pharmaceuticals Ltd, sold 14,785 shares of the company on March 1, 2024. The transaction was disclosed in an SEC Filing. Over the past year, the insider has sold a total of 24,101 shares and has not purchased any shares.
The insider transaction history for Kiniksa Pharmaceuticals Ltd shows a pattern of insider sales over the past year, with 0 insider buys and 6 insider sells recorded during the same timeframe.
On the day of the insider's recent sale, shares of Kiniksa Pharmaceuticals Ltd were trading at $21.57, giving the company a market capitalization of $1.529 billion.
The insider's trading activity may be of interest to investors and analysts monitoring insider behaviors and their correlation with the company's stock performance. However, it is important to consider the broader context of the market and the company's financial position when interpreting insider transactions.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
